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Since 2010 the new antimicrobials introduced have activity against resistant Gram negative 
bacteria, long half-lives against Gram positive bacteria, better activity against Clostridium 
difficile, and safer antifungal properties. Limiting factors to using the new antimicrobials include 
lack of susceptibility testing, cost and reimbursement issues. This article describes the new 
antimicrobials an internist will have contact with. 
 
Ceftaroline (trade name: Teflaro) is approved by the Food and Drug Administration (FDA) for 
therapy of skin and soft tissue infections and community acquired pneumonia. It is a 
cephalosporin with high affinity for PBP2a, the penicillin binding protein (PBP) associated with 
methicillin resistance. Ceftaroline is active against multi-drug resistant (MDR) Streptococcus 
pneumoniae and Staphylococcus aureus, including methicillin resistant (MRSA), vancomycin-
intermediate resistant (VISA), vancomycin resistant (VRSA), linezolid resistant and daptomycin 
non-susceptible strains. Its activity against Enterobacteriaceae mirrors ceftazidime. It has good 
activity against oral anaerobes. Ceftaroline is dosed at 600mg intravenous (IV) every 12 hours 
and the dose must be adjusted for renal failure. It has been shown to be non-inferior to 
vancomycin in soft tissue infections and to ceftriaxone in community acquired pneumonia. Its 
safety profile is similar to that of comparator drugs in clinical trials with an adverse effect profile 
similar to other cephalosporins. Intramuscular (IM) administration does not cause significant 
pain. Ceftaroline is Category B for use in pregnancy and should be used with caution in nursing 
women. Its acquisition cost of about $80/day makes it comparable to other newer agents for the 
treatment of soft tissue infections and community acquired pneumonia, but it is more costly than 
IV vancomycin, other cephalosporins and fluoroquinolones. It is less expensive than newer 
agents used to treat MRSA – linezolid, daptomycin, or tigecycline. 
 
Fidaxomicin (Dificid) is a nonabsorbed macrocyclic compound. It is the first antimicrobial 
agent approved in 25 years by the FDA for treating Clostridium difficile infections (CDI).  
Fidaxomicin is bactericidal and has been shown to be not inferior to vancomycin for treatment of 
CDI after 10 days of therapy. Fidaxomicin is superior to vancomycin for sustained response 
without recurrence 25 days after therapy completion. The indigenous fecal microbiota is 
relatively spared by fidaxomicin.  It is Category B for use in pregnancy and should be used with 
caution in nursing women. Due to its high cost (10 day course ~ $4187.50) most hospitals and 
insurance companies place restrictions on its use, allowing it for the second or third recurrence of 
CDI after first line therapy. 
 
Oritavancin (Orbactiv) and Dalbavancin (Dalvance) are long acting agents with excellent 
Gram-positive activity and chemical structures related to vancomycin.  Oritavancin inhibits 
peptidoglycan cell wall synthesis and also disrupts bacterial cell membranes. It is highly active 
against MRSA, VISA, VRSA and vancomycin resistant enterococci (VRE). A single IV dose of 
1200mg infused over 3 hours has a half-life of 393 hours, thus no repeat dosing is necessary to 
treat soft tissue infections. There is very slow elimination from tissue and no dosing adjustments 
are needed for renal or hepatic insufficiency. Trials have demonstrated noninferiority compared 
with vancomycin in the treatment of soft tissue infections. Adverse events are mostly similar to 
vancomycin except for liver enzyme elevation and the occurrence of osteomyelitis. Oritavancin 
is pregnancy risk factor C and the manufacturer recommends caution when given to nursing 
mothers. It could reduce outpatient infusion services and home care but its acquisition cost 
(~$2900) may ultimately limit its use. Also it is not a cost effective option for treatment of 
methicillin-sensitive Staphylococcus aureus (MSSA) infections, of which we see still plenty. 
Unfortunately it has yet to be assessed for treating bacteremia or bone infections. Dalbavancin 
has activity against virtually all important Gram-positive organisms with the exception of vanA-
expressing VRE. Clinical trials have demonstrated its efficacy in treating skin and soft tissue 
infections.  It has a prolonged half-life of 181 hours allowing for once-weekly dosing. It does not 
interact with the cytochrome p450 system making drug-drug interactions unlikely. No serious 
adverse events have been seen in clinical trials. Dalbavancin is pregnancy risk factor C and the 
manufacturer recommends caution when given to nursing mothers. Unfortunately there is no data 
to suggest clinical superiority over beta-lactam antibiotics or linezolid for infections due to 
susceptible organisms. Also, no sufficient data exists on its use in pneumonia or bone and joint 
infections. Also limiting its use is cost - a two dose course runs around $4470. 
 
Tedizolid (Sivextro), an oxazolidinone like Linezolid, is active against a wide range of Gram-
positive pathogens and is dosed daily. It is approved to treat skin and soft tissue infections and a 
6 day course has been shown to be non-inferior to a 10 day course of Linezolid. Some 
advantages over linezolid include less gastrointestinal and hematological side effects and lack of 
interactions with selective serotonin reuptake inhibitors. Tedizolid is pregnancy risk factor C and 
the manufacturer recommends caution when given to nursing mothers. Its pricing per dose is 
comparable to brand name Linezolid but can be used for 6 instead of 10 days for soft tissue 
infections. 
 
Gram-negative organisms have developed many resistance mechanisms to antibiotics. 
Algorithms have been published to predict a patient’s likelihood of having a resistant Gram-
negative infection looking at risk factors such as prior infection, days hospitalized, indwelling 
catheter, antibiotic exposure and age. Two novel beta-lactam/beta-lactamase combination 
antibiotics, Ceftolozane/tazobactam (Zerbaxa) and Ceftazidime/avibactam (Avycaz), are 
available to help treat MDR Gram-negatives, including Pseudomonas aeruginosa. Both are 
intravenously dosed three times a day in patients with normal renal function. In clinical trials, 
they were noninferior to comparators in the treatment of complicated urinary tract infections and 
complicated intra-abdominal infections (with metronidazole). Studies on pneumonia are 
currently being conducted. Antimicrobial stewardship will be essential to preserving their 
activity. There are no adequate and well controlled studies of Avycaz, ceftazidime, or avibactam 
in pregnant women.  Ceftolozane/tazobactam is pregnancy class B. Caution is recommended 
with both these agents when administering to nursing women. Ceftazidime/avibactam has 
activity against Klebsiella pneumoniae carbapenemase producing organisms (KPC) whereas 
Ceftolozane/tazobactam does not. Neither inactivates metallo-β-lactamases such as the New 
Delhi metallo-β-lactamases. 
 
For all the above mentioned antibiotics except Ceftaroline, no commercial sensitivity testing is 
currently available so surrogate markers or research-use-only disks can be used to help predict 
susceptibility of isolated pathogens. 
 
Peramavir (Rapivab) is a single IV dose neuraminidase inhibitor with a similar mechanism of 
action as oseltamivir and zanamavir. It is approved for adults with acute uncomplicated 
influenza. In the clinical trial for licensure, Peramavir resulted in recovery from fever 12 hours 
sooner than placebo, similar to the other neuraminidase inhibitors. No benefit was seen in serious 
flu infection in severely ill hospitalized patients. It is pregnancy risk factor C and a risk benefit 
decision should be made if considering use in nursing women. Potential indications include use 
in patients with nausea and vomiting, those requiring IV hydration or medications, patients 
wanting single dose therapy, or patients who otherwise cannot be prescribed oral or inhaled 
multi-dose therapies. 
 
Isavuconazole (Cresemba) is an extended spectrum triazole with activity against yeasts, molds, 
and dimorphic fungi.  It is approved for treatment of invasive aspergillosis and mucormycosis 
and experience is being gained in the treatment of other fungal infections. Desirable properties 
include availability of a water-soluble IV formulation, excellent oral bioavailability, and 
predictable pharmacokinetics. It inhibits fungal cell membrane ergosterol synthesis with great 
avidity for a cell wall forming protein, killing pathogens resistant to other azoles. It cannot be 
used with rifampin, carbamazepine and long-acting barbiturates as these lead to increased levels 
of isavuconazole. Sirolimus, tacrolimus and cyclosporine levels should be monitored as 
isavuconazole raises their level. Overall, when compared to voriconazole and posaconazole, 
isavuconazole seems to have fewer drug-drug interactions. It is relatively safe and well tolerated 
and has none of the side effects of voriconazole – visual disturbances, hallucinations, or 
photosensitivity. Liver enzymes should be monitored. There have been cases of infusion 
reactions in a few patients; it is recommended an in-line filter be used for infusion. 
Isavuconazole is pregnancy risk factor C and breast-feeding is not recommended by 
manufacturer. 
 
As described, these antibiotics have some unique and specific indications that can help justify 
their formulary inclusion despite high cost. Antibiotic stewardship is crucial to preserve their 
activity against MDR pathogens. Thankfully several new antibiotics with novel mechanisms of 
action are in the development pipeline. 
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